Expanding Therapeutic Potential with Novel Parvovirus Gene Therapy
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $38M
Founded date: 2021
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.06.2022 | Series A | $38M | Agent Capi... |
Mentions in press and media 3
| Date | Title | Description |
| 22.05.2024 | Carbon Biosciences Announces New Appointments to Board of Directors and Scientific Advisory Board | - Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP joins the Board of Directors, adding key clinical experience to guide ongoing nonclinical development in cardiac and pulmonary diseases - - Lloyd Klickstein, MD, PhD joins the Scientific Advisor... |
| 22.06.2022 | Carbon Biosciences Raises $38M in Series A Financing | Carbon Biosciences, a Boston, MA-based biotech company advancing novel parvovirus-derived gene therapies, raised $38m in Series A financing. The round was led by Agent Capital, which is joined by Longwood Fund, Astellas Venture Management L... |
| 22.06.2022 | As the crypto winter sets in, some VCs are taking the long view | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning. Kevin Kelleher here, filling in for Jessica who is on vacation this week. Paid Cont... |